Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour microenvironment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance 1-4 . Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogenactivated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their microenvironment can uncover important mechanisms underlying drug resistance.
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour microenvironment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance 1-4 . Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogenactivated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their microenvironment can uncover important mechanisms underlying drug resistance.
Oncoprotein-targeted drugs hold enormous promise for the future of cancer treatment. However, complete clinical responses are rare, suggesting that mechanisms exist to render a substantial proportion of tumour cells resistant to treatment. For example, melanomas harbouring a mutant BRAF gene encoding BRAF(V600E) (a mutant in which valine has been replaced with glutamic acid at residue 600) show marked responses to RAF inhibitors; however, these responses are almost always partial, and the tumours often recur within 6 months of treatment 1-4 .
We proposed that innate drug resistance might be caused, at least in part, by factors secreted by the tumour micro-environment. The growth-and metastasis-promoting effects of the micro-environment have been well documented 5, 6 , but a possible role in drug resistance has been only partially explored [7] [8] [9] [10] [11] . To test the hypothesis that stromal cells might confer innate resistance on cancer cells, we developed a coculture system whereby green fluorescent protein (GFP)-labelled tumour cells are co-cultured with stromal cells, and the ability of the stromal cells to modulate drug sensitivity is measured by monitoring the GFP levels over time ( Supplementary Fig. 1 ). Forty-five GFPlabelled human cancer cell lines were cultured either alone or in combination with a panel of up to 23 human stromal cell lines in the presence of increasing doses of 35 widely used anticancer drugs ( Supplementary Tables 1 and 2 ). Tables 3 and 4 ) showed a striking result-anticancer drugs that are capable of killing tumour cells are frequently rendered ineffective when the tumour cells are cultured in the presence of stromal cells (Fig. 1a ). For example, certain dermal fibroblasts were able to confer complete resistance to the cytotoxic agent gemcitabine on colorectal and pancreatic cancer cell lines ( Fig. 1b and Supplementary Fig. 2 ). Different stromal cells conferred resistance to RAF inhibitors on BRAF-mutant melanoma cell lines and to ERBB2 inhibitors on ERBB2-overexpressing breast cancer cell lines (Fig. 1c, d and Supplementary Figs 3 and 4 ). The stroma-mediated resistance phenomenon was particularly marked for targeted agents compared with conventional cytotoxic chemotherapy (P , 0.001; Supplementary Table 2 ). Overall, of the 23 targeted agents in the panel, there was evidence of micro-environment-mediated resistance to 15 (65%) (Supplementary Table 2 and Supplementary Information).
Our analysis of interactions between cancer cells, stromal cells and anticancer drugs (Supplementary
We next explored the mechanism of stroma-mediated innate resistance to the RAF inhibitor PLX4720 (an analogue of which, vemurafenib, was recently approved by the US Food and Drug Administration (FDA) for the treatment of BRAF-mutant melanoma). In a recent phase 3 clinical trial, 48% of patients with BRAF-mutant melanoma who were treated with vemurafenib had a confirmed response, but only 0.9% of patients had a complete response, indicating a high rate of innate resistance 2 . We tested 18 stromal cell lines for their ability to confer PLX4720 resistance on 7 BRAF(V600E) melanoma cell lines. Of these stromal cell lines, six fibroblast lines conferred resistance ( Fig. 1c and Supplementary Fig. 3 ).
To determine whether the rescue effect was mediated by direct contact between fibroblasts and tumours or by the secretion of soluble factors, we tested the ability of fibroblast-conditioned growth medium to recapitulate the resistance effect. Fibroblast-conditioned medium was able to rescue BRAF-mutant melanoma cells from PLX4720, indicating that the rescue was due to a factor secreted by the fibroblasts (Fig. 2a ). To identify the secreted factor with the rescue activity, we carried out an antibody-array-based analysis of 567 secreted factors (Supplementary Tables 5 and 6 ), comparing the conditioned medium from the 6 stromal cell lines with rescue activity to that from 12 stromal cell lines without rescue activity. The factor that correlated best with PLX4720 resistance was HGF ( Fig. 2b and Supplementary Figs 5 and 6), a well-characterized growth factor whose secretion by mesenchymal cells induces activation of the receptor tyrosine kinase MET. Although MET has been reported to be overexpressed in melanoma 12, 13 and to contribute to melanoma progression 12 , it has not previously been implicated in RAF-inhibitor resistance. However, there have been recent reports that MET activation has a potential role in the development of resistance to gefitinib, an epidermal growth factor (EGF) receptor inhibitor, in non-small-cell lung cancer 10, 14 .
We next used immunohistochemistry to examine HGF expression in 34 biopsy samples derived from patients with BRAF(V600E) melanoma that were taken immediately before treatment with a RAF inhibitor (or a combination of a RAF inhibitor and a MAPK kinase 1 (MEK1) or MEK2 inhibitor). HGF was detected in the tumour-associated stromal cells in 23 of the 34 patients (68%) (Fig. 3a, b and Supplementary Table 7 ), and phosphorylated MET (pMET) immunofluorescence studies accordingly showed MET phosphorylation (activation) in patient samples ( Supplementary Fig. 7) .
Our in vitro studies predict that the presence of stromal HGF should be associated with innate resistance. Indeed, patients whose stromal cells secreted HGF had a significantly poorer response to treatment than those lacking HGF expression (P , 0.05; Fig. 3c ). Interestingly, only 1 of the 34 patients had a durable complete response (ongoing at Relative proliferation with stromal cells Relative proliferation without stromal cells inhibitors. a, Three melanoma cell lines (vertical) were co-cultured with conditioned medium from three fibroblast cell lines (horizontal) or with fresh medium and then treated with 2 mM PLX4720. Proliferation was quantified after 7 days and compared with that of non-treated cells. The bars represent the mean 6 s.e.m. between replicates (n 5 3). b, The HGF secretion level of 18 stromal cell lines measured by a protein cytokine array ( Supplementary Table  5 ) is plotted against the ability of each stromal cell line to rescue the BRAF(V600E) melanoma cell lines from PLX4720 ( Supplementary Fig. 5 ). c, The effect of HGF (6.25-50 ng ml 21 ) on the proliferation of melanoma cell lines under PLX4720 or PD184352 treatment. The bars represent the mean 6 s.e.m. between replicates (n 5 3). d, Drug resistance manifests only in the presence of HGF-secreting stromal cells and is reversed by a MET inhibitor. Melanoma cell lines were co-cultured with nine stromal cell lines, representing HGF-secreting and non-secreting stromal cells, and treated with 2 mM PLX4720 (PLX) or 1 mM PD184352 (PD) with or without 0.2 mM crizotinib (Criz). Proliferation was quantified after 7 days and was normalized to that of non-treated cells. The results were averaged across four stromal cell lines that secrete HGF and five that do not. Non-averaged results are presented in Supplementary Fig. 11 . The bars represent the mean 6 s.e.m. between replicates (n 5 3). e, Twenty-two cytokines, each at five concentrations ( Supplementary Table 8 ), were added to six melanoma cell lines that were then treated with 2 mM PLX4720, 1 mM PD184352 or DMSO control. Proliferation was quantified after 7 days and was normalized to no-cytokine controls. The results shown are averaged for all cell lines and both drugs. The bars represent the mean 6 s.e.m. between replicates (n 5 3).
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14 months after therapy), and this patient lacked HGF expression (Supplementary Table 7 ). On-treatment biopsy samples that were taken 2 weeks after treatment initiation were also available for 10 patients. For 5 of those (50%), stromal HGF expression was higher than before treatment ( Fig. 3b and Supplementary Table 7 ). Whether this increase is attributable to the recruitment of HGF-secreting fibroblasts to the tumour or to the upregulation of HGF expression in the existing fibroblasts remains to be determined. It is notable that both normal skin and benign naevi showed stromal HGF expression ( Supplementary Fig. 8 ). Our results thus support the clinical relevance of HGF-mediated resistance to BRAF inhibitors. Importantly, a similar inverse association between plasma HGF levels and response to RAF inhibitor treatment in patients with BRAF-mutant melanoma has been found in another study 15 .
To establish HGF as the cause of drug resistance and not simply a biomarker for resistance, we tested the ability of recombinant HGF to induce resistance, as well as the ability of HGF-neutralizing antibodies or the MET-inhibitory small-molecule crizotinib to block fibroblastinduced PLX4720 resistance. These experiments indicated that HGF is both necessary and sufficient to confer the resistance phenotype (Fig. 2c, d and Supplementary Figs 9-11 ). Consistent with this observation, the extent to which 20 BRAF-mutant melanoma cell lines could be rescued by HGF was highly correlated with the MET expression level ( Supplementary Fig. 12 ).
Although our stromal-cell-profiling studies pointed to the HGF-MET axis as the most relevant in mediating PLX4720 resistance, it is conceivable that other ligands for receptor tyrosine kinases (RTKs) might similarly confer resistance. To test this possibility, we tested the ability of 22 well-characterized RTK ligands to rescue BRAFmutant melanoma cells from either PLX4720 or the MEK inhibitor PD184352. Surprisingly, despite many RTKs being expressed and activated by their cognate ligands, HGF was the only ligand that conferred substantial resistance to RAF or MEK inhibition ( Fig. 2e , Supplementary Figs 13-15 and Supplementary Table 8 ).
We next sought to clarify the precise mechanism by which the HGF-MET axis is uniquely capable of inducing primary resistance to PLX4720. MET is known to activate both the MAPK pathway (the MEK-extracellular signal-regulated kinase (ERK) pathway) and the PI(3)K pathway (the PI(3)K-AKT pathway) ( Supplementary Fig. 16 ), and both pathways have been suspected of being involved in acquired resistance to BRAF inhibitors [16] [17] [18] . We used western blot analysis to assess the ERK and AKT activation status of a panel of 7 BRAF-mutant melanoma cell lines treated with a RAF inhibitor together with various RTK ligands. HGF treatment led to the sustained activation of both ERK and AKT, but this dual activation was not observed for any of the other RTK ligands in any of the melanoma lines ( Fig. 4a and Supplementary Fig. 17 ).
It should be noted that although EGF, fibroblast growth factor 1 (FGF1) and the BB form of platelet-derived growth factor (PDGF-BB) were able to reactivate ERK in most cell lines, the levels of phosphorylated ERK (pERK) were modest compared with those of HGF-treated cells. Moreover, these ligands failed to activate AKT. Similarly, treatment with insulin or insulin-like growth factor 1 (IGF1) led to a transient increase in phosphorylated AKT (pAKT) but did not activate ERK ( Fig. 4b and Supplementary Fig. 18 ).
HGF was thus unique in its ability to induce the sustained activation of both ERK and AKT ( Fig. 4c and Supplementary Figs 19 and 20) . Importantly, we found that the HGF-mediated activation of ERK was more profound under BRAF inhibition than under MEK inhibition ( Fig. 4c and Supplementary Fig. 19 ). This might be best explained by the finding that in the presence of BRAF inhibitors, MET can reactivate MEK through RAF1 (also known as CRAF), thus bypassing BRAF; however, this pathway is not possible under conditions of direct MEK inhibition ( Fig. 4c and Supplementary Fig. 16 ).
Our model thus predicts that both the MAPK pathway and the PI(3)K-AKT pathway contribute to the primary resistance induced by HGF-secreting stromal cells. In agreement with this model, we have found that HGF-induced resistance is greater under BRAF inhibition than MEK inhibition (Fig. 2d) , that combination treatment with a BRAF inhibitor and a MEK inhibitor is not sufficient to eliminate HGF-induced resistance (as this combination does not silence AKT ( Supplementary Fig. 21) ), and that combination treatment with a MEK inhibitor and an AKT inhibitor suppresses the majority of HGFinduced drug resistance ( Supplementary Fig. 21 ).
Our discovery of HGF-mediated innate resistance to BRAF inhibitors should be distinguished from recent reports that propose the dysregulation of IGF1, PDGF, COT, BRAF or MEK as mechanisms of resistance with a poor response to therapy. a, A pre-treatment melanoma section from patient 32 was analysed for HGF expression by immunohistochemistry: black arrow, normal epidermis; red arrow, tumour cells; and blue arrow, HGFexpressing stroma (brown). A high-magnification image of the red boxed area is shown on the right. b, Melanoma sections from patient 23 were analysed for HGF expression using immunohistochemistry. The on-treatment biopsy sample was obtained 2 weeks after the initiation of treatment with the BRAF inhibitor vemurafenib (PLX4032) and 1 month after the pre-treatment biopsy was obtained. A third biopsy sample was obtained 12 months after the initiation of treatment while the patient was progressing under treatment. Highmagnification images of the red boxed areas are shown in the lower images. c, Maximal response to treatment with RAF inhibitor (RAFi), a RAFi and MEK inhibitor (MEKi) combination or the RAF inhibitor vemurafenib in patients with BRAF(V600E)-carrying melanoma that expressed or did not express stromal HGF, as determined by immunohistochemistry. Patients with stromal HGF had a significantly poorer response to treatment than those lacking HGF expression. *P , 0.05 by a two-sample t-test assuming equal variance. In the boxplots, the boxes cover the interquartile range (IQR) between the first and the third quartiles (Q1 and Q3). The whiskers are drawn at the extreme value that is no more than Q3 1 1.5 3 IQR, and no less than Q1 2 1.5 3 IQR. The median values for each group are depicted above the median line.
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to RAF inhibitors [18] [19] [20] [21] [22] . In these reports, the emergence of late (acquired) drug resistance was studied (for example, following exposure to a drug for many months), whereas we found that HGF-secreting stromal cells confer immediate (innate) resistance to RAF inhibitors. For example, the p61 splice variant of BRAF(V600E) that was recently shown to confer resistance to RAF inhibitors 21 was not observed in tumours before RAF inhibitor treatment, implicating this splice variant as a mechanism of acquired rather than innate resistance. Whether HGF has a role in acquired resistance as well remains to be determined.
Activation of the EGF receptor was recently shown to drive the resistance of some BRAF(V600E)-carrying colorectal cancer cell lines to RAF inhibitors 23, 24 . To explore a possible role for MET activation in BRAF-mutant non-melanoma cancers, we tested seven BRAFmutant non-melanoma cell lines (five colorectal cancer lines and two glioblastoma lines) and found that all seven had evidence of MET phosphorylation ( Supplementary Fig. 22 ). Although stromal HGF expression is less common in colorectal cancer than melanoma ( Supplementary Fig. 8a) , MET overexpression and HGF autocrine secretion have been documented in colorectal cancer [25] [26] [27] . Indeed, we identified two BRAF-mutant non-melanoma cell lines that secreted HGF: one colorectal cell line (RKO), and one glioblastoma cell line (KG-1-C) ( Supplementary Fig. 6 ). In these two cell lines, combined RAF and MET (but not EGF receptor) inhibition resulted in a clear synergistic effect ( Supplementary Figs 22 and 23) . The synergy between RAF and MET inhibitors was more variable among non-HGF-secreting BRAF-mutant cell lines ( Supplementary Fig. 22 ). As predicted from our proposed mechanism of resistance, monotherapy with RAF or MEK inhibitors had no effect on pAKT levels and caused little inhibition of pERK in HGF-secreting cell lines. However, dual inhibition of BRAF and MET resulted in significant inhibition of both pERK and pAKT ( Supplementary Fig. 24 ). The extent to which autocrine or micro-environment-mediated MET activation explains the failure of BRAF-mutant non-melanoma tumours to respond to BRAF inhibition deserves further investigation.
The findings reported here potentially have immediate clinical implications. Several small-molecule or antibody inhibitors of HGF or MET are in clinical development or have been approved by the FDA for other indications. Given the tolerability of those agents and the similar tolerability of RAF inhibitors, combination clinical trials in BRAF-mutant melanoma, colorectal cancer and possibly other tumour types should be considered.
It should be noted that the stroma-derived, HGF-mediated RAF inhibitor resistance mechanism detailed here was but one of many such stroma-mediated drug resistance interactions uncovered in our initial screen (Fig. 1a ). Our findings point to the micro-environment as an important but understudied source of anticancer drug resistance. Moreover, the results suggest that such resistance mechanisms can be uncovered through the systematic dissection of interactions between tumours and their micro-environment. Future studies should therefore seek to identify such resistance mechanisms for all of the drugs that are in development, potentially leading to mechanismbased combination regimens such as the RAF-and MET-inhibitor combination proposed here.
METHODS SUMMARY
Stroma-mediated chemoresistance co-culture screen. On day 0, stromal cells (1,700 cells in 20 ml per well) were plated in 384 clear-bottom plates (Corning, catalogue number 3712), together with GFP-labelled cancer cells (1,700 cells in 20 ml per well). On day 1, the cells were treated with 10 ml 53 drug using the CyBi-Well Vario 384/25 simultaneous pipettor (CyBio). On day 4, the medium in all of the wells was replaced with fresh medium, and fresh drug was added to all of the wells containing melanoma cell lines (all other cancers were treated on day 1 only). GFP fluorescence was read on days 1, 4 and 7, using a SpectraMax M5e Microplate Reader (Molecular Devices). A fluorescence microscope with high-throughput screening capabilities (Axio Observer.Z1, Zeiss) was used to document bright-field and GFP images on day 7. All screens were carried out in quadruplicate. See the Supplementary Information for a complete description of all other methods. Angiopoietin 1  Pleiotrophin   GAS6  Ephrin A4  NT3  NGF  BDNF  HGF  MSP  VEGF-C  VEGF-A  FGF1  SCF  PDGF-BB   FLT3 ligand  Insulin  IGF1  Neuregulin 1α   EGF  GDNF  Collagen II   24 
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METHODS
Stroma-mediated chemoresistance co-culture screen. On day 0, stromal cells (1,700 cells in 20 ml per well) were plated in 384 clear-bottom plates (Corning, catalogue number 3712), together with GFP-labelled cancer cells (1,700 cells in 20 ml per well). On day 1, the cells were treated with 10 ml 53 drug using the CyBi-Well Vario 384/25 simultaneous pipettor (CyBio). On day 4, the medium in all of the wells was replaced with fresh medium, and fresh drug was added to all of the wells containing melanoma cell lines (all other cancers were treated on day 1 only). GFP fluorescence was read on days 1, 4 and 7, using a SpectraMax M5e Microplate Reader (Molecular Devices). A fluorescence microscope with high-throughput screening capabilities (Axio Observer.Z1, Zeiss) was used to document brightfield and GFP images on day 7. All screens were carried out in quadruplicate.
Cell lines and reagents. The sources of all used cell lines are listed in Supplementary Table 1 . All cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen, 10569-010) with 10% FBS and 13 Pen-Strep-Glutamine (Invitrogen, 15140-122). Cancer cell lines were lentivirally transduced using the pLex_TRC206 plasmid. The sources of all used drugs are listed in Supplementary Table 2 . Antibodies specific for MET (3148), pMET (3077 and 3133), pRAF1 (9427), pERK (4370), AKT (2920), pAKT (4060), MEK (4694), pMEK (9154) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (2118) were purchased from Cell Signaling Technology. Antibody specific for RAF1 (ab656) was purchased from Abcam. Antibody specific for ERK (sc-135900) was purchased from Santa Cruz Biotechnology. Anti-rabbit (926-32211) and anti-mouse (926-32220) secondary antibodies were purchased from LI-COR.
The was purchased from Sigma. Stem cell factor (569600-10UG) was purchased from EMD. Type II collagen (ab7534) and WNT1 (ab84080) were purchased from Abcam. Skin tissue microarrays (TMAs) of normal skin, naevi and melanomas (ME1004a and ME803a) were purchased from US Biomax. Colorectal cancer TMAs were prepared as described previously 28 . Clinical samples. Patients with metastatic melanoma with the BRAF(V600E) mutation (confirmed by genotyping) were enrolled in clinical trials for treatment with a BRAF inhibitor or a combination of a RAF inhibitor and a MEK inhibitor ( Supplementary Table 7 ), and the patients gave consent for tissue acquisition as per an IRB-approved protocol. Tumours were biopsied before treatment (day 0), at 10-14 days during treatment and at the time of progression. Formalin-fixed tissue was analysed (by haematoxylin and eosin staining) to confirm that a viable tumour was present. The tumour responses were determined by the investigators according to the Response Evaluation Criteria in Solid Tumours (RECIST). Analysis of co-culture screen data. GFP fluorescence readings were measured for each well on day 7. Background fluorescence was removed from the readings by subtracting the readings for the same wells on day 1. Quadruplicates were then averaged. The drug effect on each cancer cell line in the presence or absence of stromal cells was calculated by normalizing the number of cells after 7 days of treatment (as measured by GFP fluorescence) to the number of cells (GFP) present in the dimethylsulphoxide (DMSO) control wells. The drug effect in the presence of stromal cells was normalized further to the effect that each stromal cell type had no cancer cell proliferation when no drug was present (see the 'without stroma' and 'with stroma' columns in Supplementary Table 3 ). The 'rescue score' was calculated by subtracting the 'without stroma' drug effect from the 'with stroma' drug effect. Assigning a 'rescue by stroma' score to all screened drugs. See Supplementary Table 2 for further details. Only cases in which a drug slowed the proliferation of a cancer cell line to ,30% were analysed ( Supplementary Table 4 ). Rescue was counted as positive if the rescue score was .0.3. Drugs whose activity was rescued by stromal cells in at least three cancer cell lines and in .40% of all cancer cell lines screened with this drug obtained the maximum score: 11. Drugs whose activity was rescued by stromal cells in three cancer cell lines but in only 20-40% of cancer cell lines screened with this drug scored 1, as did drugs whose activity was rescued in only 1 or 2 cell lines and in .40% of the cancer cell lines screened with this drug. Antibody arrays. Soluble proteins in the medium of the stromal cell lines were measured using the Human Cytokine Array G4000 (RayBio, AAH-CYT-G4000-8) and a Biotin Label-Based Human Antibody Array (RayBio, AAH-BLG-1-4), according to the recommended protocols. These arrays can detect 274 and 507 proteins, respectively. Stromal cells were plated 3 days before the experiment in DMEM containing 10% FBS and were 75-90% confluent when the media were collected and filtered. Medium containing 10% FBS was also hybridized to the arrays and used later for normalization. Ten technical and biological replicates were carried out, and both showed a very high correlation (correlation coefficient .0.9) (data not shown). Hybridization was carried out overnight at 4 uC. All slides were scanned using a GenePix 4000B Microarray Scanner (Axon) and analysed using the software GenePix Pro 6.0. The F532 median 2 B532 score was used and averaged across triplicates on each array. The results were then normalized using internal controls, and the values for cytokines in clear medium containing 10% FBS were subtracted. All results are available in Supplementary Tables 5 and 6 . Stroma-averaged melanoma rescue scores. The averaged melanoma rescue effect of each stromal cell line was calculated by averaging the rescue scores of this cell line ( Supplementary Table 3 ) across all melanoma cell lines and all PLX4720 concentrations. Only instances in which the treatment caused a drop in proliferation to ,0.3 when no stromal cells were present were included in this calculation.
The effect of pre-conditioned medium (PCM). PCM was prepared by filtering the medium from 80-90% confluent 15-cm plates that had been plated 3 days earlier and then diluting this medium 1:1 with fresh medium. Experiments were performed according to the previously described co-culture experiment protocol except for the following changes. First, on day 0, 384-well plates were seeded with 20 ml per well of PCM instead of 20 ml stromal cells. Second, on day 1, the medium from all of the wells was changed to fresh PCM. Third, on day 4, the medium was changed to fresh PCM instead of fresh medium before retreating the cells. Hierarchical clustering. Unsupervised hierarchical clustering of stromal cell lines according to their ability to rescue melanoma cancer cell lines from 2 mM PLX4720 (Supplementary Table 3 ) was carried out using GENE-E (http://www.broadinstitute. org/cancer/software/GENE-E/). The Euclidean distance metric was used. HGF enzyme-linked immunosorbent assay (ELISA). Cells were plated 3 days before the experiment in DMEM containing 10% FBS and were 75-90% confluent when medium was collected and filtered. An HGF ELISA was performed using a Human HGF ELISA Kit (RayBio, ELH-HGF-001) according to the kit's instructions. The medium was diluted 1:1 with diluent B before it was added to the assay microplate. For the standard HGF curve, we used the same HGF that was used for all of the other experiments (228-10702-2) and not the HGF that was supplied with the kit. The absorbance was read at 450 nm using a SpectraMax M5e Microplate Reader.
Neutralizing HGF with anti-HGF antibodies. Co-culture experiments were performed as described above except for the addition of neutralizing anti-HGF antibodies (R&D Systems, MAB294) on day 0 and after the medium was changed on day 4. Western blot analysis and quantification. Cells were plated 1 day before treatment in a 6-well plate at 5 3 10 5 cells per well, and were treated the next day. At the designated time points, cells were lysed with lysis buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1 mg ml 21 NaF, and one pellet per 10 ml each of PhosSTOP Phosphatase Inhibitor (Roche, 04906837001) and Complete Mini Protease Inhibitor (Roche). Protein concentrations were determined with a DC Protein Assay Kit II (Bio-Rad). Samples were mixed with 43 protein sample loading buffer (LI-COR, 928-40004) and NuPAGE Sample Reducing Agent (Invitrogen, NP0009), and proteins were separated on a 4-12% Bis-Tris gel (NuPAGE, WG1402BOX) at 120 V. Proteins were transferred onto membranes using Program 4 on the iBlot Gel Transfer Device (Invitrogen, IB1001). Western blot analysis was performed according to the antibody manufacturer's specifications. Near-infrared fluorescence was detected with the Odyssey Infrared Imaging System (LI-COR), and signal intensity was quantified with Odyssey Application Software (LI-COR). All values were first normalized to background intensity and then to a GAPDH loading control. High-throughput western blot analysis. High-throughput western blot analysis experiments ( Fig. 4a and Supplementary Fig. 17 ) were performed as described above, except for the following changes. First, cells were seeded in a 96-well plate at 5 3 10 4 cells per well. Second, samples were mixed with E-PAGE 43 Loading Buffer (Invitrogen, EPBUF-01), and proteins were separated on 6% E-PAGE 96-well gels (Invitrogen, EP09606). For the transfer to membranes, Program 3 of the iBlot Gel Transfer Device was used.
Rescue of melanoma cell lines by cytokines. One day before treatment, cancer cells were seeded in black 384-well plates (Corning, 3712) at a concentration of 2,500 cells per well. On day 1, all 22 ligands were added at 5 different concentrations to 6 melanoma cell lines treated with PLX4720, PD184352 or DMSO control. On day 4, the medium was changed to fresh medium, and the cells were retreated with the drugs and cytokines. GFP fluorescence was read on days 1, 4 and 7 using a SpectraMax M5e Microplate Reader. Tyrosine kinase phosphorylation profiling. Luminex immunosandwich assays were performed as previously described 29 with the following modifications. Antibodies were conjugated to MagPlex Microspheres (Luminex). The assays were carried out in 384-well Thermo Scientific Matrix square bottom plates LETTER RESEARCH
